Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma

Japan Axitinib Phase II Study Group, Fujimoto H., Nakazawa H., Matsubara N., Fujioka T., Niwakawa M., Miyazaki J., Nakamura T., Shuin T., Hasegawa Y., Tsuchiya N., Takahashi S., Nonomura N., Nishiyama K.

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences